Possible Pharmacological Effect of Quercetin in the Management of Hyperuricemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

161 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-01

Study Completion Date

2023-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Quercetin, a natural flavonoid found in various fruits and vegetables, has gained attention for its potential role in managing hyperuricemia. Emerging evidence suggests that quercetin may reduce plasma uric acid levels by inhibiting xanthine oxidase, an enzyme responsible for uric acid production. Additionally, its anti-inflammatory and antioxidant properties could help mitigate the oxidative stress and inflammation associated with hyperuricemia. As a result, quercetin supplementation offers a promising avenue for therapeutic intervention in conditions like gout and other uric acid-related disorders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutraceutical on Hyperuricemia

NCT04161872

Hyperuricemia

COMPLETED PHASE4

Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia

NCT05913310

Hyperuricemia

UNKNOWN PHASE4

The Effects of a Probiotic Food Supplement in Hyperuricaemia

NCT07141888

Hyperuricemia With or Without Gout

NOT_YET_RECRUITING NA

Clinical Efficacy Trial of Burdock Root Extract in Patients With Asymptomatic Hyperuricaemia

NCT07002762

Hyperuricemia or Gout

RECRUITING NA

Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects

NCT04966325

Hyperuricemia Gout Qt Interval, Variation in

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the present retrospective cross-sectional observational study, the investigators assessed the potential pharmacological effect of supplemental quercetin on the plasma uric acid levels of health adults. These participants visited nutritional clinics in Italy during the Coronavirus disease (COVID-19) pandemic for general health check-up in real-life to enhance their immune system with supplements aimed at providing additional protection against COVID-19 infection. The supplements, either quercetin or probiotic Streptococcus salivarius K12 (BLIS K12), were advised randomly to the participants for 90 days, tailored to individual needs and in the absence of any pre-defined criteria.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperuricemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supplemental Quercetin group

These participants received oral 500 mg Quevir® (Quercetin Phytosome®) tablet, twice a day for 90 days. Each Quevir® tablet contains 200 mg pure Quercetin.

Quevir® (Quercetin Phytosome®)

Intervention Type DIETARY_SUPPLEMENT

500 mg Quevir® (Quercetin Phytosome®) tablet

Supplemental Probiotic Strptococcus salivarius K12 (ATCC BAA-1024) group

These participants received orally dissolving Bactoblis® tablet, once daily before bedtime for 90 days. Each Bactoblis® tablet contains at least 1x10⁹ CFU of probiotic S. salivarius K12 (ATCC BAA-1024).

Bactoblis®

Intervention Type DIETARY_SUPPLEMENT

Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Quevir® (Quercetin Phytosome®)

500 mg Quevir® (Quercetin Phytosome®) tablet

Intervention Type DIETARY_SUPPLEMENT

Bactoblis®

Probiotic Streptococcus Salivarius K12 (ATCC BAA-1024)

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Quevir®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults
* BMI between 18.5 and 29.9 kg/m²
* Non-smoker
* Consumtion of less than 3 units of alcohol per day

Exclusion Criteria

* \- Plasma uric acid concentrations above 7 mg/dL
* Diagnosis of endocrinological, metabolic, oncological, neurological, or bowel inflammatory disease diseases, gout, kidney stones

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes